Work

Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses

Year: 2026
Type: article
Abstract: SARS-CoV, SARS-CoV-2, and MERS-CoV continue to infect humans or pose a threat of future outbreaks, highlighting the ongoing need for effective, broad-spectrum therapeutics that target these highly pathogenic coronaviruses. As single-domain antibodies, nanobodies have a small size, high target-binding affinity, exceptional stability, low production costs, and the ability to access otherwise hidden or cryptic epitopes. Here, we identified nanobodies targeting SARS-CoV, SARS-CoV-2, and MERS-CoV receptor-binding domains (RBDs) using phage display libraries derived from immunized nanomice and generated a bispecific nanobody to evaluate its broadly neutralizing activity and cross-protective efficacy. Nanobodies 2F11 and 4D6 targeted SARS-CoV RBD, potently neutralizing the SARS-CoV original (Tor2) strain, whereas nanobody 3B11 targeted both SARS-CoV and SARS-CoV-2 RBDs, broadly neutralizing all three SARS-CoV strains (Tor2, GD03, and SZ3) and divergent SARS-CoV-2 variants. Among MERS-CoV RBD-targeting nanobodies, 1C11 demonstrated broadly neutralizing activity against multiple MERS-CoV strains, while its Fc-fused version substantially enhanced the neutralizing potency. These nanobodies exerted neutralizing effects by blocking the interaction between the RBDs and their respective receptors. Cryo-EM structures, computational modeling, and epitope-mapping analyses revealed unique epitopes of 2F11, 3B11, and 1C11 on the SARS-CoV, SARS-CoV-2, or MERS-CoV RBD, underlying their antiviral potency. Finally, a bispecific nanobody 3B11–1C11-Fc that binds to the SARS-CoV, SARS-CoV-2, and MERS-CoV RBDs exhibited high stability and robust cross-neutralizing activity against all tested SARS-CoV, SARS-CoV-2, and MERS-CoV strains, protecting mice from infection with these three coronaviruses. Overall, the identified nanobodies, particularly the bispecific nanobody, exhibit strong neutralizing potency and protective efficacy against SARS-CoV, SARS-CoV-2, and MERS-CoV, showing the potential for further therapeutic development.
Source: ACS Nano
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W7234195628
FWCI:
Cites: 78
Cited by:
Related to: 10